LOGIN-VSI
29.7.2020 14:32:11 CEST | Business Wire | Press release
HTG – Howell Technology Group, the specialised supplier of innovative IT and security solutions, today announced that it has signed a supplier agreement with Login VSI , the company dedicated to maximising the end-user experience.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200729005078/en/
Delivered through a customer-centric approach, HTG’s professional and trusted IT consulting services enables customers to operate sustainably and achieve efficiencies gained from transformation of their IT environments to modern, cloud-based workspaces.
This partnership will focus on the provision of specialist solutions and services as part of the ecosystem for Windows Virtual Desktop (WVD). Working closely with Microsoft as a Gold partner, HTG is already deploying WVD to some impressive accounts as a cloud-based, remote working solution. Adding Login VSI to this mix represents an opportunity for HTG to join forces with the market leader in synthetic user testing.
Kevin Howell, CTO, HTG said, “Sizing end-user compute solutions to deliver optimal user experience and performance can be complex. Using Login VSI allows us to deliver our services in a performant and efficient manner.”
For Login VSI, this partnership represents the opportunity to work with a highly regarded consultant. Using their specialised skills, HTG will be able to efficiently deploy Login Enterprise into their customer base – delivering to them application compatibility testing, load testing, as well as performance and availability testing in a single platform.
Since the onset of COVID, there has been an increased demand for enterprise IT organisations to support a global remote working model. Testing of a scaled-up remote infrastructure has therefore become critical. Login VSI provides comprehensive testing and validation of the entire technology stack, from the core to the endpoint. It maximises the scalability and availability of applications and virtual desktop environments, including cloud. Login Enterprise, Login VSI’s flagship product, enables enterprises to quickly identify potential performance or availability issues by measuring and comparing application load times and application responsiveness. It is this expertise that will provide added value to HTG’s services within the digital workspace and especially as part of the WVD ecosystem.
Graham Wight, CEO, HTG commented: “We are excited about the opportunity to work with Login VSI. With the recent shift in demand for technologies that enable the smooth and secure transition to remote working, there is a greater need for performance and availability testing. The addition of this service under the partnership can only enhance and add value to the services we provide our customers.”
“We are excited about the opportunity to work with HTG,” said Eric-Jan van Leeuwen, CEO of Login VSI. “Given the global shift to remote working, there is a greater need for performance and availability testing, in order to ensure business continuity. With HTG’s superior knowledge of the WVD market and the unrivalled experience they have, we believe this is the beginning of a long-lasting relationship.”
About HTG
HTG is a leading global IT solutions company offering a range of disruptive technologies and best in class products. We work closely with customers from a wide range of industries to enable efficiencies through transformation of their IT environments and help simplify the way our IT services are delivered to them. Our digital knowledge and expertise in the latest technologies enables us to help our customers define their digital vision and strategic roadmap, delivering real and impactful change.
For further information please visit www.htguk.com or contact us on 0191 481 3446 .
About Login VSI
Login VSI is the only solution in the market guaranteed to maximize the end-user experience for digital workspaces. We reduce risk and ensure business continuity by safeguarding application and desktop performance. We do this using synthetic users to automatically test and validate the impact of change in physical, virtual and cloud-based workspaces.
Our flagship product, Login Enterprise integrates application compatibility testing, load testing, as well as performance & availability testing into a single platform. Login Enterprise also includes standard “out-of-the-box” application template workloads. Login VSI has over 400 customers in 50 countries. For more information, visit www.loginvsi.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005078/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom